ASU Anti-Cancer Center discussed possible cooperation options with BIOCAD Company

19 October 2017 Department of Information and Media Communications
Executive Director of Russian-American Anti-Cancer Center under Altai State University, Candidate of Biology Andrey I. Shapoval participated in BiotechClub 2017, the first scientific conference in a new format.

The conference, where the scientist from Altai State University acted as a speaker, was held on the premises of I.M. Sechenov First Moscow State Medical University. Andrey I. Shapoval delivered a report in the framework of “When Will We Kill Cancer” section and participated in “The Future of Immunotherapy for Malignant Tumors”.

“At the conference I presented two directions of research carried out by Russian-American Anti-Cancer Center at Altai State University. They are early breast cancer detection and prediction of response to immunotherapy with the help of immunosignature method,” Andrey I. Shapoval specified. “For the present day, the usage of blocking agents for immune checkpoints is one of the most promising directions in cancer immune therapy. However, the therapeutic effect of this method is observed only in 30% of cases. At the same time, preliminary results of immunosignature research have shown that this method allows detecting patients, whose organisms will respond to cancer immune therapy, and those, who will not experience any therapeutic effect.”

According to Andrey I. Shapoval, BiotechClub 2017 appeared to be a site for discussion of a wide range of questions related to diagnostic and immune therapy of oncologic diseases. ASU representative’s speech resulted in the fact that a number of Moscow medical companies showed their interest towards cooperation with Russian-American Anti-Cancer Center at the flagship university of Altai Krai.

“One of the conference organizers, BIOCAD Company, is currently performing clinical trials of immunotherapeutic drugs for cancer therapy. We are interested in the usage of samples, which they will receive in the course of the clinical trials, that is why we discussed possible cooperation options with our colleagues. We conducted negotiations with representatives of other Moscow medical organizations as well,” Executive Director of Anti-Cancer Center summarized.

Printable version